This HTML5 document contains 138 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00950/identifier/wikipedia/
n9http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00950/identifier/pharmgkb/
n29http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00950/identifier/kegg-compound/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n32http://linked.opendata.cz/resource/drugbank/mixture/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00950/identifier/bindingdb/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00950/identifier/pubchem-compound/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00950/identifier/pubchem-substance/
n11http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00950/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n13http://www.rxlist.com/cgi/generic/
n4http://linked.opendata.cz/resource/drugbank/patent/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00950/identifier/national-drug-code-directory/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n28http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n14http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00950/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00950/identifier/chebi/
n31http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00950
rdf:type
n3:Drug
n3:description
Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine. Fexofenadine, like other second and third-generation antihistamines, does not readily pass through the blood-brain barrier, and so causes less drowsiness than first-generation histamine-receptor antagonists.
n3:dosage
n5:271B40F2-363D-11E5-9242-09173F13E4C5 n5:271B40EF-363D-11E5-9242-09173F13E4C5 n5:271B40F0-363D-11E5-9242-09173F13E4C5 n5:271B40F1-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Smith SM, Gums JG: Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19545214 # Bachert C: A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19539095 # Markham A, Wagstaff AJ: Fexofenadine. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9506246 # Golightly LK, Greos LS: Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs. 2005;65(3):341-84. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15669879 # Molimard M, Diquet B, Benedetti MS: Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15312146
n3:group
approved
n3:halfLife
14.4 hours
n3:indication
For management of Seasonal allergic rhinitis
n3:manufacturer
n7:271B40DC-363D-11E5-9242-09173F13E4C5 n7:271B40DD-363D-11E5-9242-09173F13E4C5 n7:271B40E0-363D-11E5-9242-09173F13E4C5 n7:271B40E1-363D-11E5-9242-09173F13E4C5 n7:271B40DE-363D-11E5-9242-09173F13E4C5 n7:271B40DF-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00950 n17:DB00950
dcterms:title
Fexofenadine
adms:identifier
n19:5050 n20:3231 n21:22874 n22:C06999 n23:0339-6461-11 n24:DB00950 n25:46504676 n26:PA449621 n27:3348 n30:Fexofenadine
n3:mechanismOfAction
Like other H1-blockers, Fexofenadine competes with free histamine for binding at H1-receptors in the GI tract, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Fexofenadine exhibits no anticholinergic, antidopaminergic, alpha1-adrenergic or beta-adrenergic-receptor blocking effects.
n3:packager
n7:271B40DA-363D-11E5-9242-09173F13E4C5 n7:271B40DB-363D-11E5-9242-09173F13E4C5 n7:271B40D8-363D-11E5-9242-09173F13E4C5 n7:271B40D9-363D-11E5-9242-09173F13E4C5 n7:271B40D6-363D-11E5-9242-09173F13E4C5 n7:271B40D7-363D-11E5-9242-09173F13E4C5 n7:271B40D4-363D-11E5-9242-09173F13E4C5 n7:271B40D5-363D-11E5-9242-09173F13E4C5 n7:271B40D2-363D-11E5-9242-09173F13E4C5 n7:271B40D3-363D-11E5-9242-09173F13E4C5 n7:271B40D0-363D-11E5-9242-09173F13E4C5 n7:271B40D1-363D-11E5-9242-09173F13E4C5 n7:271B40CE-363D-11E5-9242-09173F13E4C5 n7:271B40CF-363D-11E5-9242-09173F13E4C5 n7:271B40CC-363D-11E5-9242-09173F13E4C5 n7:271B40CD-363D-11E5-9242-09173F13E4C5 n7:271B40CA-363D-11E5-9242-09173F13E4C5 n7:271B40CB-363D-11E5-9242-09173F13E4C5 n7:271B40C8-363D-11E5-9242-09173F13E4C5 n7:271B40C9-363D-11E5-9242-09173F13E4C5 n7:271B40C6-363D-11E5-9242-09173F13E4C5 n7:271B40C7-363D-11E5-9242-09173F13E4C5 n7:271B40C4-363D-11E5-9242-09173F13E4C5 n7:271B40C5-363D-11E5-9242-09173F13E4C5 n7:271B40C2-363D-11E5-9242-09173F13E4C5 n7:271B40C3-363D-11E5-9242-09173F13E4C5 n7:271B40C0-363D-11E5-9242-09173F13E4C5 n7:271B40C1-363D-11E5-9242-09173F13E4C5 n7:271B40BE-363D-11E5-9242-09173F13E4C5 n7:271B40BF-363D-11E5-9242-09173F13E4C5 n7:271B40BC-363D-11E5-9242-09173F13E4C5 n7:271B40BD-363D-11E5-9242-09173F13E4C5 n7:271B40BA-363D-11E5-9242-09173F13E4C5 n7:271B40BB-363D-11E5-9242-09173F13E4C5 n7:271B40B8-363D-11E5-9242-09173F13E4C5 n7:271B40B9-363D-11E5-9242-09173F13E4C5 n7:271B40B6-363D-11E5-9242-09173F13E4C5 n7:271B40B7-363D-11E5-9242-09173F13E4C5 n7:271B40B4-363D-11E5-9242-09173F13E4C5 n7:271B40B5-363D-11E5-9242-09173F13E4C5 n7:271B40B3-363D-11E5-9242-09173F13E4C5
n3:patent
n4:6037353 n4:2301267 n4:5178878 n4:2134211
n3:synonym
Terfenadine carboxylate Fexofenadine Terfenadine acid metabolite Carboxyterfenadine Terfenadine-COOH 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid
n3:toxicity
Side effects include dizziness, drowsiness, and dry mouth.
n8:hasAHFSCode
n9:04-08-00
n3:foodInteraction
Take without regard to meals. Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly decrease serum levels of this product.
n3:mixture
n32:271B40B2-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
60%-70%
n3:synthesisReference
Federico Milla, "Processes for the production of fexofenadine." U.S. Patent US20030166682, issued September 04, 2003.
n28:hasConcept
n29:M0245918
foaf:page
n13:fexofen.htm n14:fexofenadine.html
n3:IUPAC-Name
n6:271B40F7-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B40FD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B40FC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B40F9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B40FA-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B40FB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B40F5-363D-11E5-9242-09173F13E4C5 n6:271B410D-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B40F6-363D-11E5-9242-09173F13E4C5 n6:271B40F3-363D-11E5-9242-09173F13E4C5 n6:271B410F-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B40F4-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n31:R06AX26
n3:H-Bond-Acceptor-Count
n6:271B4103-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B4104-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B40FE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B40FF-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B4101-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B4100-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B4102-363D-11E5-9242-09173F13E4C5
n3:absorption
33%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
83799-24-0
n3:category
n3:containedIn
n16:271B40E7-363D-11E5-9242-09173F13E4C5 n16:271B40E8-363D-11E5-9242-09173F13E4C5 n16:271B40E5-363D-11E5-9242-09173F13E4C5 n16:271B40E6-363D-11E5-9242-09173F13E4C5 n16:271B40E3-363D-11E5-9242-09173F13E4C5 n16:271B40E4-363D-11E5-9242-09173F13E4C5 n16:271B40E2-363D-11E5-9242-09173F13E4C5 n16:271B40ED-363D-11E5-9242-09173F13E4C5 n16:271B40EE-363D-11E5-9242-09173F13E4C5 n16:271B40EB-363D-11E5-9242-09173F13E4C5 n16:271B40EC-363D-11E5-9242-09173F13E4C5 n16:271B40E9-363D-11E5-9242-09173F13E4C5 n16:271B40EA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B4109-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B410B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B410C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B410E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B4108-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B4107-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B410A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B40F8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B4105-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B4106-363D-11E5-9242-09173F13E4C5